This patent allowance is a routine IP event for a pre-revenue clinical-stage biotech with a $3M market cap. No financial data or clinical catalysts are provided. Monitor for future partnering announcements or clinical trial updates on IM1240, but the filing itself does not warrant a trading action.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 2 $1.98entry
- T+1 · 3mo ago 0.00%α −1.05% · $1.98
- T+5 · 2mo ago −12.12%α −11.16% · $1.74
- T+20 · 7w ago −23.23%α −23.15% · $1.52
- T+52 · todayOpen
- T+60 · in 10d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Purple Biotech announced a USPTO Notice of Allowance for a patent covering tri-specific antibody constructs and methods of use, strengthening IP protection for its CAPTN-3 modular platform. This is a routine IP milestone for a clinical-stage company with a $3M market cap and no revenue, providing no near-term financial catalyst.
Key Facts
- USPTO issued Notice of Allowance for patent application covering tri-specific antibody constructs and methods of use.
- Patent strengthens IP protection for CAPTN-3 modular platform for conditionally activated multispecific antibodies.
- Lead candidate IM1240 is advancing toward the clinic; second candidate IM1305 is in preclinical development.
- Company market cap is approximately $3M with no reported revenue from the filing.
Financial Impact
No financial figures disclosed; patent allowance is an IP milestone with no immediate revenue or cost impact.
Risk Factors
- No revenue or near-term commercialization path disclosed.
- Lead candidate IM1240 is still pre-clinical; clinical-stage assets (CM24, NT219) require partnering or investment to advance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-096443 |
| Document: ea0304192-6k_purple.htm | 0001213900-26-096443 |
| Document: 0001213900-26-096443-index-headers.html | 0001213900-26-096443 |
| Document: 0001213900-26-096443-index.html | 0001213900-26-096443 |
| Document: 0001213900-26-096443.txt | 0001213900-26-096443 |
Track record
14 reports on PPBT
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago SC 13G Neutral 3/10 Entry $1.56 Now $1.68 +7.69% settles Feb 10
- Nov 12, 20265d ago EFFECT Neutral 3/10 Entry $1.56 Now $1.68 +7.69% settles Feb 10
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $1.49 Now $1.68 +12.75% settles Feb 9
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $1.09 Now $1.68 +54.13% settles Jan 27
- Oct 5, 20266w ago 6-K Neutral 2/10 Entry $1.47 Now $1.68 +14.29% settles Dec 31
- Sep 9, 20269w ago 6-K Neutral 2/10 Entry $1.74 Now $1.68 −3.45% settles Dec 4
- Sep 2, 202610w ago 6-K Neutral 3/10 Viewing Entry $1.98 Now $1.68 −15.15% settles Nov 27
- Aug 10, 202614w ago 6-K Neutral 4/10 Entry $1.55 to $1.22 Now $1.68 +8.39% ▼ −21.61% −21.13% vs SPY
- Aug 7, 202614w ago 6-K Neutral 4/10 Entry $1.43 to $1.22 Now $1.68 +17.48% ▼ −14.69% −12.55% vs SPY
- May 15, 202626w ago Press Release Neutral 4/10 Entry $3.94 to $1.55 Now $1.68 −57.36% ▼ −60.66% −65.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers